Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin

Wataru Tomisato, Ken Ichiro Tanaka, Shinji Tsutsumi, Tatsuya Hoshino, Kazumi Yokomizo, Keitarou Suzuki, Takashi Katsu, Tohru Mizushima, Tohru Mizushima

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Nitric oxide (NO) releasing non-steroidal anti-inflammatory drugs (NSAIDs) have shown a marked reduction of gastrointestinal side effects and we here examined the cytotoxicity of NCX 530 (NO-indomethacin). Under conditions where indomethacin clearly induced both necrosis and apoptosis, NCX 530 induced neither. NCX 530 protected cells from celecoxib-induced necrosis and apoptosis. NCX 530 partially suppressed celecoxib-dependent membrane permeabilization and an inhibitor for guanylate cyclase suppressed the cytoprotective effect of NCX 530 against celecoxib. In vivo, NCX 530 alone produced fewer gastric lesions in rats than did indomethacin. A combination of the oral administration of celecoxib together with the intraperitoneal administration of indomethacin, but not of NCX 530, clearly resulted in the production of gastric lesions. The low direct cytotoxicity and the cytoprotective effect of NCX 530 observed in vitro may also act in vivo, thus ensuring that NCX 530 is safe for use on the gastric mucosa.

Original languageEnglish
Pages (from-to)1927-1937
Number of pages11
JournalDigestive Diseases and Sciences
Volume50
Issue number10
DOIs
Publication statusPublished - 2005 Oct
Externally publishedYes

Fingerprint

Celecoxib
Indomethacin
Nitric Oxide
Stomach
Necrosis
Apoptosis
1-(4-chlorobenzoyl)-5-methoxy-2-1H-indole-3-acetic acid 3-(nitrooxymethyl)phenyl ester
Guanylate Cyclase
Gastric Mucosa
Oral Administration
Anti-Inflammatory Agents
Membranes
Pharmaceutical Preparations

Keywords

  • Cyclooxygenase
  • Direct cytotoxicity
  • Gastric lesion
  • Indomethacin
  • NO-NSAID
  • Selective cyclooxygenase-2 inhibitor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Tomisato, W., Tanaka, K. I., Tsutsumi, S., Hoshino, T., Yokomizo, K., Suzuki, K., ... Mizushima, T. (2005). Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin. Digestive Diseases and Sciences, 50(10), 1927-1937. https://doi.org/10.1007/s10620-005-2963-4

Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin. / Tomisato, Wataru; Tanaka, Ken Ichiro; Tsutsumi, Shinji; Hoshino, Tatsuya; Yokomizo, Kazumi; Suzuki, Keitarou; Katsu, Takashi; Mizushima, Tohru; Mizushima, Tohru.

In: Digestive Diseases and Sciences, Vol. 50, No. 10, 10.2005, p. 1927-1937.

Research output: Contribution to journalArticle

Tomisato, W, Tanaka, KI, Tsutsumi, S, Hoshino, T, Yokomizo, K, Suzuki, K, Katsu, T, Mizushima, T & Mizushima, T 2005, 'Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin', Digestive Diseases and Sciences, vol. 50, no. 10, pp. 1927-1937. https://doi.org/10.1007/s10620-005-2963-4
Tomisato, Wataru ; Tanaka, Ken Ichiro ; Tsutsumi, Shinji ; Hoshino, Tatsuya ; Yokomizo, Kazumi ; Suzuki, Keitarou ; Katsu, Takashi ; Mizushima, Tohru ; Mizushima, Tohru. / Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin. In: Digestive Diseases and Sciences. 2005 ; Vol. 50, No. 10. pp. 1927-1937.
@article{7499c3bbe17d4e219f57cf76142ec48d,
title = "Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin",
abstract = "Nitric oxide (NO) releasing non-steroidal anti-inflammatory drugs (NSAIDs) have shown a marked reduction of gastrointestinal side effects and we here examined the cytotoxicity of NCX 530 (NO-indomethacin). Under conditions where indomethacin clearly induced both necrosis and apoptosis, NCX 530 induced neither. NCX 530 protected cells from celecoxib-induced necrosis and apoptosis. NCX 530 partially suppressed celecoxib-dependent membrane permeabilization and an inhibitor for guanylate cyclase suppressed the cytoprotective effect of NCX 530 against celecoxib. In vivo, NCX 530 alone produced fewer gastric lesions in rats than did indomethacin. A combination of the oral administration of celecoxib together with the intraperitoneal administration of indomethacin, but not of NCX 530, clearly resulted in the production of gastric lesions. The low direct cytotoxicity and the cytoprotective effect of NCX 530 observed in vitro may also act in vivo, thus ensuring that NCX 530 is safe for use on the gastric mucosa.",
keywords = "Cyclooxygenase, Direct cytotoxicity, Gastric lesion, Indomethacin, NO-NSAID, Selective cyclooxygenase-2 inhibitor",
author = "Wataru Tomisato and Tanaka, {Ken Ichiro} and Shinji Tsutsumi and Tatsuya Hoshino and Kazumi Yokomizo and Keitarou Suzuki and Takashi Katsu and Tohru Mizushima and Tohru Mizushima",
year = "2005",
month = "10",
doi = "10.1007/s10620-005-2963-4",
language = "English",
volume = "50",
pages = "1927--1937",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin

AU - Tomisato, Wataru

AU - Tanaka, Ken Ichiro

AU - Tsutsumi, Shinji

AU - Hoshino, Tatsuya

AU - Yokomizo, Kazumi

AU - Suzuki, Keitarou

AU - Katsu, Takashi

AU - Mizushima, Tohru

AU - Mizushima, Tohru

PY - 2005/10

Y1 - 2005/10

N2 - Nitric oxide (NO) releasing non-steroidal anti-inflammatory drugs (NSAIDs) have shown a marked reduction of gastrointestinal side effects and we here examined the cytotoxicity of NCX 530 (NO-indomethacin). Under conditions where indomethacin clearly induced both necrosis and apoptosis, NCX 530 induced neither. NCX 530 protected cells from celecoxib-induced necrosis and apoptosis. NCX 530 partially suppressed celecoxib-dependent membrane permeabilization and an inhibitor for guanylate cyclase suppressed the cytoprotective effect of NCX 530 against celecoxib. In vivo, NCX 530 alone produced fewer gastric lesions in rats than did indomethacin. A combination of the oral administration of celecoxib together with the intraperitoneal administration of indomethacin, but not of NCX 530, clearly resulted in the production of gastric lesions. The low direct cytotoxicity and the cytoprotective effect of NCX 530 observed in vitro may also act in vivo, thus ensuring that NCX 530 is safe for use on the gastric mucosa.

AB - Nitric oxide (NO) releasing non-steroidal anti-inflammatory drugs (NSAIDs) have shown a marked reduction of gastrointestinal side effects and we here examined the cytotoxicity of NCX 530 (NO-indomethacin). Under conditions where indomethacin clearly induced both necrosis and apoptosis, NCX 530 induced neither. NCX 530 protected cells from celecoxib-induced necrosis and apoptosis. NCX 530 partially suppressed celecoxib-dependent membrane permeabilization and an inhibitor for guanylate cyclase suppressed the cytoprotective effect of NCX 530 against celecoxib. In vivo, NCX 530 alone produced fewer gastric lesions in rats than did indomethacin. A combination of the oral administration of celecoxib together with the intraperitoneal administration of indomethacin, but not of NCX 530, clearly resulted in the production of gastric lesions. The low direct cytotoxicity and the cytoprotective effect of NCX 530 observed in vitro may also act in vivo, thus ensuring that NCX 530 is safe for use on the gastric mucosa.

KW - Cyclooxygenase

KW - Direct cytotoxicity

KW - Gastric lesion

KW - Indomethacin

KW - NO-NSAID

KW - Selective cyclooxygenase-2 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=26244432445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244432445&partnerID=8YFLogxK

U2 - 10.1007/s10620-005-2963-4

DO - 10.1007/s10620-005-2963-4

M3 - Article

C2 - 16187199

AN - SCOPUS:26244432445

VL - 50

SP - 1927

EP - 1937

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 10

ER -